Published in Cell Mol Life Sci on August 13, 2010
VDR/RXR and TCF4/β-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Mol Endocrinol (2011) 1.46
Activation of PAD4 in NET formation. Front Immunol (2012) 1.30
The protein arginine deiminases: Structure, function, inhibition, and disease. Biopolymers (2013) 1.18
Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer (2012) 1.18
Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis. Biochem Res Int (2012) 1.08
Citrullination of inhibitor of growth 4 (ING4) by peptidylarginine deminase 4 (PAD4) disrupts the interaction between ING4 and p53. J Biol Chem (2011) 1.01
Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy. Cancers (Basel) (2011) 1.00
Chemical biology of protein arginine modifications in epigenetic regulation. Chem Rev (2015) 0.99
Autodeimination of protein arginine deiminase 4 alters protein-protein interactions but not activity. Biochemistry (2011) 0.95
Potential role for PADI-mediated histone citrullination in preimplantation development. BMC Dev Biol (2012) 0.95
Functional role of dimerization of human peptidylarginine deiminase 4 (PAD4). PLoS One (2011) 0.91
The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. PLoS One (2013) 0.91
Metal impurities cause false positives in high-throughput screening campaigns. ACS Med Chem Lett (2012) 0.89
Chemical and biological methods to detect post-translational modifications of arginine. Biopolymers (2014) 0.88
Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer. Cancer Med (2014) 0.88
PAD4 regulates proliferation of multipotent haematopoietic cells by controlling c-myc expression. Nat Commun (2013) 0.87
Development and use of clickable activity based protein profiling agents for protein arginine deiminase 4. ACS Chem Biol (2011) 0.86
Citrullinated histone H3: a novel target for the treatment of sepsis. Surgery (2014) 0.86
PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation. Nat Commun (2014) 0.85
The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer. Cancer Gene Ther (2015) 0.81
Chemical Proteomic Platform To Identify Citrullinated Proteins. ACS Chem Biol (2015) 0.79
Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation. Curr Drug Targets (2015) 0.79
PADI4 has genetic susceptibility to gastric carcinoma and upregulates CXCR2, KRT14 and TNF-α expression levels. Oncotarget (2016) 0.77
A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy. J Extracell Vesicles (2015) 0.77
Protective effect of Cl-amidine against CLP-induced lethal septic shock in mice. Sci Rep (2016) 0.75
Molecular Interplay between the Dimer Interface and the Substrate-Binding Site of Human Peptidylarginine Deiminase 4. Sci Rep (2017) 0.75
Peptidylarginine Deiminases as Drug Targets in Neonatal Hypoxic-Ischemic Encephalopathy. Front Neurol (2016) 0.75
Fluorescence-based monitoring of PAD4 activity via a pro-fluorescence substrate analog. J Vis Exp (2014) 0.75
Cl-Amidine Prevents Histone 3 Citrullination and Neutrophil Extracellular Trap Formation, and Improves Survival in a Murine Sepsis Model. J Innate Immun (2016) 0.75
B-cell specific Moloney leukemia virus insert site 1 and peptidyl arginine deiminase IV positively regulate carcinogenesis and progression of esophageal squamous cell carcinoma. Oncol Lett (2017) 0.75
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol (2007) 6.16
Human PAD4 regulates histone arginine methylation levels via demethylimination. Science (2004) 5.46
Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol (2009) 5.27
Histone deimination antagonizes arginine methylation. Cell (2004) 5.19
PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays (2003) 5.04
Binary switches and modification cassettes in histone biology and beyond. Nature (2003) 4.75
The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol (2001) 3.92
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem (2006) 3.15
Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry (2006) 2.92
DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst (2005) 2.43
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res (2003) 2.40
Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol (2008) 2.27
Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem (2008) 1.93
Molecular characterization of peptidylarginine deiminase in HL-60 cells induced by retinoic acid and 1alpha,25-dihydroxyvitamin D(3). J Biol Chem (1999) 1.93
A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J Am Chem Soc (2006) 1.85
Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. Curr Opin Drug Discov Devel (2009) 1.83
Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer (2009) 1.78
Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol Carcinog (2006) 1.70
Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene (1996) 1.58
Immunocytochemical localization of peptidylarginine deiminase in human eosinophils and neutrophils. J Leukoc Biol (2001) 1.36
Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res (2006) 1.32
Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother Rep (1976) 1.28
Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells. Cell Growth Differ (1993) 1.27
Activity-based protein profiling reagents for protein arginine deiminase 4 (PAD4): synthesis and in vitro evaluation of a fluorescently labeled probe. J Am Chem Soc (2006) 1.24
Purification and characterization of small molecular weight myeloperoxidase from human promyelocytic leukemia HL-60 cells. Biochemistry (1981) 1.24
Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans (2002) 1.16
An improved synthesis of haloaceteamidine-based inactivators of protein arginine deiminase 4 (PAD4). Tetrahedron Lett (2008) 1.13
Estrogen-enhanced peptidylarginine deiminase type IV gene (PADI4) expression in MCF-7 cells is mediated by estrogen receptor-alpha-promoted transfactors activator protein-1, nuclear factor-Y, and Sp1. Mol Endocrinol (2007) 1.11
Functional connection between deimination and deacetylation of histones. Mol Cell Biol (2009) 1.10
Thrombin increases the metastatic potential of tumor cells. Int J Cancer (1993) 1.02
Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med (2005) 1.02
Down-regulation of telomerase activity is an early event in the differentiation of HL60 cells. Biochem Biophys Res Commun (1996) 0.96
Mechanism-based small molecule probes for labeling CD38 on live cells. J Am Chem Soc (2009) 0.90
Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol (1998) 0.89
The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Cell Cycle (2004) 0.89
Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. Eur J Cell Biol (2008) 0.86
Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry (2006) 2.92
The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature (2008) 2.83
Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol (2008) 2.27
Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis. Biochemistry (2005) 2.21
N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol (2011) 2.18
Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem (2008) 1.93
Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res (2014) 1.93
A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J Am Chem Soc (2006) 1.85
Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. Curr Opin Drug Discov Devel (2009) 1.83
Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry (2010) 1.66
Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest (2013) 1.64
Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol (2011) 1.61
Protein arginine methyltransferase 1: positively charged residues in substrate peptides distal to the site of methylation are important for substrate binding and catalysis. Biochemistry (2007) 1.55
Protein arginine deiminase 4: evidence for a reverse protonation mechanism. Biochemistry (2007) 1.45
In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1. J Am Chem Soc (2008) 1.42
Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular chromatin traps. Arthritis Rheum (2011) 1.38
Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor α target gene activation. Proc Natl Acad Sci U S A (2012) 1.35
Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells. PLoS Genet (2011) 1.33
Kinetic mechanism of protein arginine methyltransferase 1. Biochemistry (2008) 1.32
Activation of PAD4 in NET formation. Front Immunol (2012) 1.30
Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors. ACS Chem Biol (2011) 1.25
Activity-based protein profiling reagents for protein arginine deiminase 4 (PAD4): synthesis and in vitro evaluation of a fluorescently labeled probe. J Am Chem Soc (2006) 1.24
The protein arginine deiminases: Structure, function, inhibition, and disease. Biopolymers (2013) 1.18
Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer (2012) 1.18
A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem Commun (Camb) (2010) 1.13
An improved synthesis of haloaceteamidine-based inactivators of protein arginine deiminase 4 (PAD4). Tetrahedron Lett (2008) 1.13
Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation. Chembiochem (2010) 1.13
The protein acetyltransferase ARD1: a novel cancer drug target? Curr Cancer Drug Targets (2008) 1.13
Protein deiminases: new players in the developmentally regulated loss of neural regenerative ability. Dev Biol (2011) 1.12
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem (2007) 1.11
Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis. Biochem Res Int (2012) 1.08
Peptide borono lectins (PBLs): a new tool for glycomics and cancer diagnostics. Chembiochem (2007) 1.06
Kinase consensus sequences: a breeding ground for crosstalk. ACS Chem Biol (2011) 1.04
A selective chemical probe for coenzyme A-requiring enzymes. Angew Chem Int Ed Engl (2007) 1.04
Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo. Nanomedicine (Lond) (2012) 1.00
Chemical biology of protein arginine modifications in epigenetic regulation. Chem Rev (2015) 0.99
Kinetic mechanism of protein arginine methyltransferase 6 (PRMT6). J Biol Chem (2012) 0.95
Potential role for PADI-mediated histone citrullination in preimplantation development. BMC Dev Biol (2012) 0.95
Autodeimination of protein arginine deiminase 4 alters protein-protein interactions but not activity. Biochemistry (2011) 0.95
Seeing citrulline: development of a phenylglyoxal-based probe to visualize protein citrullination. J Am Chem Soc (2012) 0.93
Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300. Bioorg Med Chem (2003) 0.93
Mechanistic studies on transcriptional coactivator protein arginine methyltransferase 1. Biochemistry (2011) 0.93
A chloroacetamidine-based inactivator of protein arginine methyltransferase 1: design, synthesis, and in vitro and in vivo evaluation. Chembiochem (2010) 0.91
Selective HAT inhibitors as mechanistic tools for protein acetylation. Methods Enzymol (2004) 0.91
The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. PLoS One (2013) 0.91
Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors. J Med Chem (2015) 0.90
Substrate specificity, processivity, and kinetic mechanism of protein arginine methyltransferase 5. Biochemistry (2013) 0.90
The tomato brassinosteroid receptor BRI1 increases binding of systemin to tobacco plasma membranes, but is not involved in systemin signaling. Plant Mol Biol (2009) 0.89
Chemical and biological methods to detect post-translational modifications of arginine. Biopolymers (2014) 0.88
Characterization and inactivation of an agmatine deiminase from Helicobacter pylori. Bioorg Chem (2009) 0.88
Activity-based protein profiling of protein arginine methyltransferase 1. ACS Chem Biol (2011) 0.88
Inhibiting AMPylation: a novel screen to identify the first small molecule inhibitors of protein AMPylation. ACS Chem Biol (2013) 0.87
Probing adenylation: using a fluorescently labelled ATP probe to directly label and immunoprecipitate VopS substrates. Mol Biosyst (2012) 0.87
A combinatorial approach to characterize the substrate specificity of protein arginine methyltransferase 1. Mol Biosyst (2010) 0.86
D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy. ACS Med Chem Lett (2012) 0.86
Design, synthesis, and kinetic characterization of protein N-terminal acetyltransferase inhibitors. ACS Chem Biol (2013) 0.86
Development and use of clickable activity based protein profiling agents for protein arginine deiminase 4. ACS Chem Biol (2011) 0.86
Mechanistic studies of protein arginine deiminase 2: evidence for a substrate-assisted mechanism. Biochemistry (2014) 0.85
Protein arginine methyltransferase 5 catalyzes substrate dimethylation in a distributive fashion. Biochemistry (2014) 0.84
Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates. J Neurochem (2014) 0.84
Automethylation of protein arginine methyltransferase 8 (PRMT8) regulates activity by impeding S-adenosylmethionine sensitivity. J Biol Chem (2013) 0.83
Targeting the arginine phosphatase YwlE with a catalytic redox-based inhibitor. ACS Chem Biol (2013) 0.82
Mechanistic studies of agmatine deiminase from multiple bacterial species. Biochemistry (2010) 0.82
Human protein N-terminal acetyltransferase hNaa50p (hNAT5/hSAN) follows ordered sequential catalytic mechanism: combined kinetic and NMR study. J Biol Chem (2012) 0.81
A FluoPol-ABPP PAD2 high-throughput screen identifies the first calcium site inhibitor targeting the PADs. ACS Chem Biol (2014) 0.81
Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors. Bioorg Med Chem (2004) 0.80
A novel role for protein arginine deiminase 4 in pluripotency: the emerging role of citrullinated histone H1 in cellular programming. Bioessays (2014) 0.80
Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation. Curr Drug Targets (2015) 0.79
Boronic acid functionalized peptidyl synthetic lectins: combinatorial library design, peptide sequencing, and selective glycoprotein recognition. ACS Comb Sci (2011) 0.77
Using unnatural amino acid mutagenesis to probe the regulation of PRMT1. ACS Chem Biol (2014) 0.75
Methyllysine analogs: rewriting the code. Nat Chem Biol (2007) 0.75
Atomic force microscopy characterization and lithography of Cu-ligated mercaptoalkanoic acid "molecular ruler" multilayers. Langmuir (2014) 0.75
1-Adamantanethiol as a versatile nanografting tool. Scanning (2014) 0.75
Synthesis and evaluation of 2-ethynyl-adenosine-5'-triphosphate as a chemical reporter for protein AMPylation. Org Biomol Chem (2015) 0.75